(Total Views: 242)
Posted On: 12/11/2018 8:12:04 PM
Post# of 72433
The FDA had ALL data on the trial prior to granting the eop2 meeting. They would not have granted the meeting if they thought sample size was a problem going to phase3.
Go IPIX!
Go IPIX!
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)